Urea, N,N'-diphenyl-N-(3-(4-(phenylmethyl)-1-piperidinyl)propyl)- | 333795-14-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: Urea, N,N'-diphenyl-N-(3-(4-(phenylmethyl)-1-piperidinyl)propyl)-
• 英文别名: 1-[3-(4-benzylpiperidin-1-yl)propyl]-1,3-diphenylurea
• CAS: 333795-14-5
• 化学式: C₂₈H₃₃N₃O
• 分子量: 427.6
• InChiKey: GQZSBYCMCKQSTQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  35.6
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• METHODS FOR REDUCING VIRAL LOAD IN HIV-1-INFECTED PATIENTS
  申请人：CytoDyn, Inc.

  公开号：EP1910573B1

  公开（公告）日：2013-09-04
• METHODS FOR TREATING OR PREVENTING CANCERS INVOLVING THE ADMINISTRATION OF ANTI-CCR5 RECEPTOR AGENTS
  申请人：CytoDyn Inc.

  公开号：EP4007603A1

  公开（公告）日：2022-06-08
• Methods for reducing viral load in HIV-1-infected patients
  申请人：Olson C. William

  公开号：US20070026441A1

  公开（公告）日：2007-02-01

  This method provides a method for reducing HIV-1 viral load in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval effective HIV-1 viral load-reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of an HIV-1-associated disorder, the inhibition of which is effected by inhibiting fusion of HIV-1 to CCR5 + CD4 + target cells in the subject. This invention also provides a method for treating a subject infected with HIV-1 comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4 + cells and (ii) inhibits fusion of HIV-1 to the subject's CCR5 + CD4+ cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.
• COMBINATION THERAPY FOR HUMAN IMMUNODEFICIENCY VIRUS INFECTION
  申请人：Friedman A. Paul

  公开号：US20080108586A1

  公开（公告）日：2008-05-08

  The present invention is directed to combination therapies for treatment of Human Immunodeficiency Virus (HIV) infection comprising administration of a CCR5 antagonist in combination with other therapeutic agents.
• Methods of inhibiting HIV-2 infection
  申请人：Ketas Thomas J.

  公开号：US20090074766A1

  公开（公告）日：2009-03-19

  This invention provides methods of inhibiting HIV-2 infection of a susceptible cell by HIV-2 which comprises subjecting the susceptible cell to an effective HIV-2 infection inhibiting dose of a humanized antibody designated PRO 140, or of an anti-CCR5 receptor monoclonal antibody, wherein the effective HIV- 1 infection inhibiting dose comprises from 0.1 mg per kg to 25 mg per kg of the subject's body weight, so as to thereby inhibit the infection of the susceptible cell by HIV-2.